Explore

Bioengineering Advances: Hybrid Living Models Enhance Vascular Disease Research

Bioengineering Advances: Hybrid Living Models Enhance Vascular Disease Research

Recent developments in bioengineering have introduced hybrid living models that integrate both the bath and bioink as active components. These models are particularly promising for creating perfusable tubes with stiffness gradients and spatial heterogeneity of cell types, which are crucial for reconstructing vascularized tissue microenvironments. This approach allows for the exploration of interactions between arteries and their surrounding tissue environment, providing insights into various vascular diseases. The models are designed to mimic the structural and functional aspects of human vessels, enabling researchers to study the etiology of vascular diseases more effectively. The focus is on developing disease-aligned toolchains, including standardized bioinks and validated perfusion protocols, to deliver actionable physiological insights.

ARPA-H Grant to Advance Genomic Medicines for Rare Vascular Diseases

ARPA-H Grant to Advance Genomic Medicines for Rare Vascular Diseases

Massachusetts General Hospital has received a significant grant from the Advanced Research Projects Agency for Health (ARPA-H) to develop genomic medicines for rare vascular diseases. The grant, part of the THRIVE program, aims to create a scalable gene-editing platform to treat severe genetic vasculopathies such as Multisystemic Smooth Muscle Dysfunction Syndrome and Generalized Arterial Calcification of Infancy. The initiative, known as VESSEL, focuses on delivering durable therapies directly to vascular cells, potentially offering one-time treatments for multiple diseases. This project involves collaboration among various research institutes and aims to reduce development timelines and costs, ultimately expanding patient access to these therapies.

N-Zyme Biomedical Raises $4.6 Million to Advance Reflux Disease Treatment

N-Zyme Biomedical Raises $4.6 Million to Advance Reflux Disease Treatment

N-Zyme Biomedical Raises $4.6 Million to Advance Reflux Disease Treatment

N-Zyme Biomedical Secures $4.6 Million Series A Funding to Advance Reflux Disease Treatment

N-Zyme Biomedical Secures $4.6 Million Series A Funding to Advance Reflux Disease Treatment

N-Zyme Biomedical Secures $4.6 Million Series A Funding to Advance Reflux Disease Treatment

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

MOTS-C Peptide Emerges as Potential Obesity Treatment Amid FDA Review

MOTS-C Peptide Emerges as Potential Obesity Treatment Amid FDA Review

The MOTS-C peptide is gaining attention as a potential treatment for obesity, distinct from the popular GLP-1 peptides. Although not yet approved for human use, MOTS-C is noted for its energy-boosting effects and is being explored for its ability to mimic exercise's biological effects. It activates AMPK, a key enzyme in energy regulation, which may enhance glucose uptake and fat metabolism. Current research includes a 12-week clinical trial to assess its effectiveness in adults with obesity and prediabetes. The FDA is reviewing MOTS-C among other peptides for potential inclusion in the 503A Bulks List, which would allow its use in compounded medications.

Ashlins Pharmaceuticals Secures Exclusive License with Lee's Pharm for Interferon Alpha-2b Development

Ashlins Pharmaceuticals Secures Exclusive License with Lee's Pharm for Interferon Alpha-2b Development

Ashlins Pharmaceuticals Secures Exclusive License with Lee's Pharm for Interferon Alpha-2b Development

UCSD and IGI Partner to Advance CRISPR Innovations in Health and Environment

UCSD and IGI Partner to Advance CRISPR Innovations in Health and Environment

The University of California, San Diego (UCSD) has joined forces with the Innovative Genomics Institute (IGI) to enhance CRISPR technology applications in health and environmental sectors. Founded by Nobel laureate Jennifer Doudna, the IGI aims to translate gene editing successes into practical solutions for societal challenges. This partnership marks UCSD as the fourth UC partner, joining UC Berkeley, UC San Francisco, and UC Davis. The collaboration focuses on developing genome-editing tools to address issues like antibiotic-resistant infections and climate change. UCSD's strengths in environmental and marine sciences, engineering, and biomedical research complement IGI's mission to create scalable and accessible solutions.

New Center for Therapeutic Genetics Launched to Tackle Rare Diseases

New Center for Therapeutic Genetics Launched to Tackle Rare Diseases

The Broad Institute, Boston Children's Hospital, and The Jackson Laboratory have launched the Center for Therapeutic Genetics (CTG) to develop genetic medicines for rare and ultra-rare diseases. The collaboration aims to create precision medicines using advanced genetic editing techniques like base and prime editing. The center will focus on making these treatments scalable and accessible, sharing methods and data to facilitate broader application.

Cellares and Papillon Therapeutics Collaborate to Automate Gene Therapy Manufacturing for Friedreich's Ataxia

Cellares and Papillon Therapeutics Collaborate to Automate Gene Therapy Manufacturing for Friedreich's Ataxia

Cellares and Papillon Therapeutics Collaborate to Automate Gene Therapy Manufacturing for Friedreich's Ataxia

An HIV vaccine is within reach

An HIV vaccine is within reach

But politics could derail the one thing to unlock it.

Jasper Therapeutics and Kira Pharma Merge to Form Immunology-Focused Biotech

Jasper Therapeutics and Kira Pharma Merge to Form Immunology-Focused Biotech

Jasper Therapeutics and Kira Pharma Merge to Form Immunology-Focused Biotech